Dimension Therapeutics, Inc., a Cambridge, MA-based rare disease company advancing novel, liver-directed treatments for diverse genetic disorders, completed a $65m Series B financing.
The round was led by new investor New Leaf Venture Partners with participation from additional new investors Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, and Tourbillon Global Ventures, and another life sciences investor as well as existing investors Fidelity Biosciences and OrbiMed. In association with the financing, Mike Dybbs, Ph.D., Partner, New Leaf Venture Partners, joined Dimension’s Board of Directors.
The company intends to use the funds to further advance its adeno-associated virus (AAV) platform and the pipeline of gene therapy programs. The first program is expected to enter clinical testing in patients with hemophilia B in the second half of 2015. Additional programs to treat indications in rare diseases are anticipated to enter IND-enabling studies during the next 12 to 18 months, with the objective of advancing three clinic-ready programs next year.
Led by CEO Annalisa Jenkins, Dimension Therapeutics is a rare disease company focused on developing novel treatments for devastating disorders associated with the liver and based on an extensively validated adeno-associated virus (AAV) platform. The company is advancing multiple programs toward clinical development, including a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015.